CD24 and COVID-19: In another clinical trial study, the safety and potential effectiveness of CD24-Exosome (EXO-CD24), a protein with anti-inflammatory properties, were evaluated in two tertiary care hospitals in Athens, Greece, in patients hospitalized with severe COVID-19.